Thelansis

  Tenosynovial giant cell tumour (TGCT) is a proliferative monoarticular lesion that occurs in and around joints throughout the body. TGCT is a group of lesions that develop from the synovium of joints, bursae, and tendon sheaths. There are two main subtypes of TGCT: localized-type TGCT (L-TGCT) and diffuse-type TGCT (D-TGCT). L-TGCT and D-TGCT behave differently and are categorized as separate clinical entities. Pain, swelling, stiffness, and limited range of motion are common symptoms. Other functional signs include instability, giving way and joint blockage. However, these nonspecific presentations can cause a delay in diagnosis and multiple visits to medical professionals. TGCT gene expression is consistent with apoptosis resistance, inflammation, and matrix degradation, resulting in ongoing proliferation and joint destruction. CD53, ALOX5AP, SPP1, and MMPs 1 and 9 are among the genes that are highly overexpressed. Complete excision of TGCT is the primary choice of treatment. Depen